MOGN Mgi Pharma (MM)

MGI PHARMA, INC. (Nasdaq:MOGN) today announced that it will present at the Lazard Capital Markets Life Sciences Conference on Tuesday, November 29, at 8:00 a.m. Eastern Time. Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA, will give the presentation, which will be webcast live over the Internet. The conference will be held at The New York Palace Hotel in New York City. -0- *T What: MGI PHARMA's presentation at the Lazard Capital Markets Life Sciences Conference When: Tuesday, November 29, 2005 at 8:00 a.m. Eastern Time How: Live over the Internet - simply log on to www.mgipharma.com. In addition to the live webcast, the presentation will be archived on the Company's Web site for one week. *T About MGI PHARMA MGI PHARMA, INC. is an oncology and acute care focused biopharmaceutical company that acquires, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets. For more information about MGI PHARMA, please visit www.mgipharma.com. This news release contains certain "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements are not guarantees of MGI PHARMA's future performance and involve a number of risks and uncertainties that may cause actual results to differ materially from the results discussed in these statements. Factors that might cause either company's results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, the ability of MGI PHARMA's product candidates to be proven safe and effective in humans, to receive marketing authorization from regulatory authorities, and to ultimately compete successfully with other therapies; continued sales of MGI PHARMA's marketed products; development or acquisition of additional products; reliance on contract manufacturing; changes in strategic alliances; continued access to capital; ability of MGI PHARMA to successfully complete the integration of Guilford with its existing operations; the risk that the perceived advantages of the Guilford transaction may not be achieved; and other risks and uncertainties detailed from time to time in MGI PHARMA's filings with the Securities and Exchange Commission including its most recently filed Form 10-Q or 10-K. MGI PHARMA undertakes no duty to update any of these forward-looking statements to conform them to actual results.